Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04112199
Recruitment Status : Recruiting
First Posted : October 2, 2019
Last Update Posted : October 29, 2021
Sponsor:
Information provided by (Responsible Party):
BioVie Inc.

Brief Summary:
This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of ascites and complications in adult patients with refractory ascites secondary to decompensated cirrhosis

Condition or disease Intervention/treatment Phase
Ascites Decompensated Cirrhosis Drug: BIV201 continuous infusion Phase 2

Detailed Description:

Terlipressin has been shown to reduce portal hypertension, improve renal function and induce natriuresis in cirrhotic patients with ascites without hepatorenal syndrome (HRS). It is approved in Europe for the treatment of bleeding esophageal varices and HRS type 1 and is usually administered as an IV bolus starting at 1 mg every 6 h and increased to 2 mg every 6 h (maximum 8 mg/day depending on response).

This study will evaluate the use of terlipressin delivered by continuous infusion for two 28 day treatment cycles for reduction of ascites accumulation and complications in adult patients with refractory ascites secondary to decompensated cirrhosis. Continuous infusion allows for a significant reduction in the daily effective dose required for treatment and improved safety of terlipressin delivered as a low-dose continuous infusion could enable its use in the outpatient setting in the prolonged treatment of patients with refractory ascites.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Thirty patients will be randomized to either BIV201 continuous infusion plus SOC or SOC alone.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites
Actual Study Start Date : June 17, 2021
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis

Arm Intervention/treatment
Experimental: BIV201 plus Standard of Care
BIV201 continuous infusion - treatment for two 28 day cycles.
Drug: BIV201 continuous infusion
BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
Other Name: terlipressin diacetate

No Intervention: Standard of care
Per AASLD guidelines: diuretics and therapeutic paracentesis



Primary Outcome Measures :
  1. Incidence of complications, at least grade 2 severity [ Time Frame: 180 days following randomization ]
    Incidence of complications, at least grade 2, during the 180 days following randomization


Secondary Outcome Measures :
  1. Change in cumulative ascites [ Time Frame: 12 weeks ]
    Change in cumulative ascites during the first 12 weeks following randomization versus the 12 weeks pre-treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Informed consent prior to any study-related procedures
  • Male or female patients age 18 to 75 years old
  • Cirrhosis of the liver (Non-alcoholic steatohepatitis, alcohol, viral and autoimmune)
  • Patient has diuretic-resistant, intractable ascites or is unsuitable for treatment with diuretics and required:

    o In the 60-day period from the last LVP before consent, required, between 3 and 9 LVPs, including the last LVP on or before the day of consent.

  • Dates for all LVPs that occurred within 90 days prior to consent have been recorded. The volume of ascites removed at each of the LVPs must also have been recorded for the 90-day period prior to the last LVPs before consent
  • Serum creatinine (SCr) ≤2.00 mg/dL determined prior to randomization
  • Women of child-bearing potential (e.g. not post-menopausal for at least one year or surgically sterile) must be neither pregnant nor lactating and must agree to use adequate birth control or be abstinent for the duration of the study
  • If patient is treated with ACE inhibitors or beta blockers, dose has been stable for at least 30 days prior to randomization and may be maintained on that dose for the trial duration
  • If patient is treated with diuretics, patient has been on a stable daily dose for at least 10 days prior to consent
  • Willing and able to comply with trial instructions

Exclusion Criteria

  • Ascites with causes other than cirrhosis; such as cardiac or nephrogenic ascites or malignant ascites due to peritoneal carcinomatosis
  • Urinary sodium excretion >100 mmol/day between day of consent and randomization
  • Total bilirubin >5 mg/dL
  • Blood clotting International normalized ratio (INR) >2.5
  • Current or recent (within 3 months of consent) renal replacement therapy
  • Current or recent (within 3 month of consent) hepatic encephalopathy Grade 3 or 4 (West-Haven)
  • Superimposed acute liver failure/injury due to factors including acute alcoholic hepatitis, acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom [Amanita] poisoning)
  • History or presence of hepatic hydrothorax, known pulmonary hypertension and a history of hepatopulmonary syndrome
  • Current or recent treatment (within 7 days of randomization) with octreotide, midodrine, vasopressin, dopamine or other vasopressors
  • Current or recent (in the previous 60 days from consent) episode of respiratory failure requiring positive airway pressure (PAP) devices or intubation
  • Sepsis episode in the previous 28 days from consent
  • Episode of SBP within the 28 days prior to consent
  • Episode of gastrointestinal hemorrhage (non-variceal) within 28 days prior to consent
  • Episode of esophageal variceal bleed within one week prior to consent
  • Ongoing documented or suspected infection
  • Severe cardiovascular disease that is a contraindication to terlipressin therapy such as a history of myocardial infarction, angina pectoris, advanced arteriosclerosis, uncontrolled cardiac arrhythmia, severe coronary insufficiency or uncontrolled hypertension
  • Findings suggestive of severe organic renal disease (severe proteinuria/hematuria, or abnormal renal ultrasound suggestive of obstructive renal pathology)
  • Use of nephrotoxic drugs (e.g., aminoglycosides) in the 4 weeks before screening
  • Severe comorbidity that in the opinion of the Investigator would affect short-term prognosis and/or disallow safe participation in the trial (such as for example, severe anemia or pancytopenia, advanced progressive neoplasia such as hepatocellular carcinoma, unless eligible for transplant)
  • Patient who, in the judgment of the investigator, has been an excessive alcohol drinker in the past 12 weeks
  • Patient is in the opinion of the investigator, despite previous education on sodium restriction, anticipated to remain grossly non-compliant of sodium restricted diet
  • Implanted alfapump or previous recipient of alfapump that had pump removed within past 3 months
  • Recipient of renal or liver transplant
  • Planned elective surgery related to cirrhosis complications, for example for hernia repair
  • Known allergy or hypersensitivity to terlipressin
  • Participation in other clinical research studies involving the treatment with other investigational drugs or evaluation with implantable devices within 30 days of consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04112199


Contacts
Layout table for location contacts
Contact: Penelope Markham, PhD 7035989972 pmarkham@biovieinc.com
Contact: Jonathan M Adams 3123265971 jadams@biovieinc.com

Locations
Layout table for location information
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90095
Contact: Connie Landon    310-825-7876    clandon@mednet.ucla.edu   
Principal Investigator: Sammy Saab, MD         
United States, Florida
Mayo Clinic Jacksonville Recruiting
Jacksonville, Florida, United States, 32224
Contact: Robert Brannock    904-953-4133    Brannock.robert@mayo.edu   
Principal Investigator: Andrew Keaveney, MD         
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Lourdes Olson    305-243-6939    malourdes@med.miami.edu   
Contact: Sonia Carvalho    3052434639    scarvalho@med.miami.edu   
Principal Investigator: Eric Martin, MD         
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Michael Mijares    305-243-6405    mmijares74@med.miami.edu   
Principal Investigator: Paul Martin         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Amy Olofson    507-538-6547    olofson.amy@mayo.edu   
Principal Investigator: Douglas Simonetto, MD         
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Calvin Trisolini    215-615-3755    calvin.trisolini@pennmedicine.upenn.edu   
Principal Investigator: Rajender Reddy, MD         
Principal Investigator: Ethan Weinberg, MD         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Christian Conley    843-876-4273    conleyc@musc.edu   
Principal Investigator: David Koch, MD         
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37212
Contact: Kathryn Campbell    615-343-5683    Kathryn.Campbell@vumc.org   
Principal Investigator: Michael Porayko, MD         
United States, Virginia
Hunter Holmes McGuire Veterans Affairs Medical Center Recruiting
Richmond, Virginia, United States, 23249
Contact: Edie Gavis, RN       edie.gavis@va.gov   
Principal Investigator: Jasmohan Bajaj, MD         
Sponsors and Collaborators
BioVie Inc.
Investigators
Layout table for investigator information
Study Director: Giacomo Basadonna, MD BioVie Inc.
Layout table for additonal information
Responsible Party: BioVie Inc.
ClinicalTrials.gov Identifier: NCT04112199    
Other Study ID Numbers: CIT-002
First Posted: October 2, 2019    Key Record Dates
Last Update Posted: October 29, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: De-identified individual participant data for primary and secondary end-points may be made available after NDA filing.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioVie Inc.:
Terlipressin
Refractory ascites
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Fibrosis
Ascites
Pathologic Processes
Liver Diseases
Digestive System Diseases
Terlipressin
Antihypertensive Agents
Vasoconstrictor Agents